Global Herpes Zoster Treatment Market Report to 2030 – Players Include Bausch Health, Cipla and Camber Pharmaceuticals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Herpes Zoster Treatment Market by Treatment Type Route Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.

The global herpes zoster treatment market was valued at $217.09 million in 2020, and is projected to reach $303.42 million by 2030, registering a CAGR of 3.4% from 2021 to 2030.

Herpes zoster (shingles) is a viral infection, caused due to the varicella-zoster virus. It is usually a painful rash on the skin that causes flickering, torment, and itchy blisters on the back, chest, and face and spreads to The rest of the body. Symptoms typically start with pain along the affected dermatome, which is followed by an enlarged vesicular eruption in 2-3 days. Symptoms include lymph nodes, fever, chills, and headache, itching, raised dots on skin and redness in that area, stabbing or shooting pain, tingling, or burning feeling in or under the skin, and upset stomach.

Anyone who gets herpes zoster has a history of chickenpox, often decades earlier. These two conditions come from the same virus, called varicella zoster. In addition, individuals with herpes zoster can infect another person who never had chicken pox, yet the individual will foster chicken pox and not herpes zoster. Herpes zoster is pervasive in older adults as they have weak immune system. Individuals going through radiation treatment or chemotherapy have weakened immune system and are more inclined to get herpes zoster sickness.

In addition, PCR can be used to detect VZV DNA rapidly and sensitively, and is now widely available. After the analysis of herpes zoster, drug is given for treatment, which incorporates oral medications and antibodies. Antihistamines, desensitizing creams, gels, or fixes are given to lessen the agony. Vaccines are given to more established individuals who have a higher risk of acquiring herpes zoster.

Herpes zoster occurs due to reactivation of varicella zoster virus in older age and the incidences of herpes zoster is higher in geriatric population compared to adults and children. For instance, in 2021, the U.S. reported that the risk of herpes zoster increases with age. It has been expected that the incidence of herpes zoster in the U.S. will increase with increasing older age population.

Moreover, increase in geriatric population, coupled with rising incidences of herpes zoster also contribute toward growth of the market. However, dearth of skilled professionals is expected to hinder growth of the market. Conversely, increase in drug development provides lucrative growth opportunities to the market.

Key Benefits

• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global herpes zoster treatment market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region-& country-wise analysis is provided to understand the market trends and dynamics

Market Dynamics

Driver

• Increase in geriatric population, coupled with rise in incidences of herpes zoster

Restraint

• Dearth of skilled professionals

Opportunities

• R&D investments by pharmaceutical companies

Key Market Segments

By Treatment Type

• Antiviral Medications
• Anti-inflammatory Medications
• Other

By Route of Administration

• Oral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Provider

By Region

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Australia
• Japan
• China
• India
• South Korea
• Rest of Asia-Pacific
• LAMEA
• Brazil
• Saudi Arabia
• South Africa

Key Players

• Abbott Laboratory
• Bausch Health
• Cipla Inc.
• Camber Pharmaceuticals.
• GlaxoSmithKline plc
• Merck
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Co.
• Teva Pharmaceutical Industries Ltd

For more information about this report visit https://www.researchandmarkets.com/r/85qw2s

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900